Share
Under the Skin
Achieving better health outcomes for patients
Season 1, Ep. 5
•
This podcast is aimed at healthcare professionals, produced and funded by UCB.
In our fifth episode, our host, Dr Barry McGrath, PhD, is joined by Dr Antonio Martorell, a leading physician from Spain, to discuss the evolving landscape of care in hidradenitis suppurativa (HS). Together, they delve into the importance of individualised treatment approaches, the role of shared decision-making in patient care, and the promising future of HS management. The conversation also highlights emerging diagnostic and treatment techniques, including the use of technology and AI to better support patients remotely.
Speaker disclosures:
Dr Barry McGrath has received consulting fees, research or institutional support and educational grants from UCB; he has received consultancy/advisory board disease-related honoraria from Novartis and UCB.
Antonio Martorell has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, AbbVie, Janssen-Cilag, UCB, Lilly, LEO Pharma, L’Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squibb and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB, Janssen, Bristol Myers Squibb, Lilly, Galderma, Sanofi and Novartis.
More episodes
View all episodes
3. Episode 3: The evolving role of ultrasound in HS
14:49||Season 2, Ep. 3his podcast is aimed at healthcare professionals, produced and funded by UCB. In episode 3, our host, Prof Monika Arenbergerová speaks with fellow ultrasound expert Prof Valentina Dini. Prof Dini tells us about how ultrasound works in HS, differentiating between different types of HS lesions with ultrasound, and how we can use the updated guidelines and ultrasound to optimise diagnosis. HS: Hidradenitis Suppurativa Prof Monika Arenbergerová has received support from UCB, AbbVie, and Novartis. Prof Valentina Dini has received support from AbbVie, Eli Lilly, Johnson & Johnson, Sanofi, Convatec, Almirall , Leo Pharma, UCB, Novartis , Boehringer Ingelheim.2. HS Management: Combining surgery and medical treatments
24:36||Season 2, Ep. 2This podcast is aimed at healthcare professionals, produced and funded by UCB. Episode 2 brings together two surgical experts – our host, Prof Monika Arenbergerová and Prof Eva Vilarrasa. Together, they discuss the evolution of the use of surgery in HS, the use of biological treatments, and how we can combine both surgical and medical management of HS to improve outcomes. HS: Hidradenitis Suppurativa Prof Monika Arenbergerová has received support from UCB, AbbVie, and Novartis. Prof Eva Vilarrasa has received research support, speaker/consultant fees and honoraria, and served as an advisory board member for AbbVie, Acelyrin, Almirall, Amgen, Bayer, Biofrontera AG, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galderma, Gebro Pharma, Incyte, ISDIN, Johnson & Johnson, Leo Pharma, Eli-Lilly, Merck Serono, MoonLake Immunotherapeutics, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, iDermApp, Mediktor, Dermus Pharma, BIOMI Life Sciences, HSCalc, and Barcelona Health Hub.
1. How will the new European S2k guidelines change clinical practice?
30:01||Season 2, Ep. 1This podcast is aimed at healthcare professionals, produced and funded by UCB. In episode 1, our host, Prof Monika Arenbergerová, chats about updates in the most recent S2k clinical guidelines for hidradenitis suppurativa, with two of its co-authors: Dr Aikaterini Liakou and Dr Alejandro Molina Leyva. Together, they discuss changes in diagnosis, treatment recommendations, and their own personal experiences of putting the guidelines into practice. Prof Monika Arenbergerová has received support from UCB, AbbVie, and Novartis. Dr Aikaterini I. Liakou has received advisory board fees from Novartis and UCB and lecture honoraria and support for attending meetings from Amgen, AbbVie, Boehringer Ingelheim, Novartis and UCB Pharma. She is a sub-investigator in clinical trials of AbbVie, Boehringer Ingelheim, Insmed, Novartis, Sanofi and UCB. Dr Alejandro Molina Leyva has received support for attending meetings, served as an advisory board member and participated in clinical trials for AbbVie, Novartis, MoonLake Immunotherapeutics, MSD, Sanofi, Incyte, Pfizer, Indero, Almirall and UCB.
4. Patient expectations and different perspectives of HS.
34:45||Season 1, Ep. 4This podcast is aimed at healthcare professionals, produced and funded by UCB. In our fourth episode, our host Dr Barry McGrath, PhD, is joined by Dr Fiona Collier, a former general practitioner from Scotland, and Laurelle-Maria Sterling, a patient with HS who is very active in HS support networks. Together, they explore public perceptions of HS, the views of dermatologists, and their own hopes for the future of HS treatment and awareness. Speaker disclosures: Dr Barry McGrath has received consulting fees, research or institutional support and educational grants from UCB; he has received consultancy/advisory board disease-related honoraria from Incyte, Novartis, and UCB. Dr Fiona Collier has received consulting fees and speaker honoraria from UCB. Laurelle-Maria Sterling has received honorarium from UCB for this podcast.
3. Why is there a delay in HS patient diagnosis?
31:44||Season 1, Ep. 3This podcast is aimed at healthcare professionals, produced and funded by UCB. For our third episode, our host Dr Barry McGrath, PhD, is joined by Dr Philippe Guillem, hidradenitis suppurativa Surgeon from Lyon, France. On this episode, they explore the various barriers to, and the consequences of, an HS diagnosis, and discuss how we can work towards achieving an earlier diagnosis together. Speaker disclosures: Dr Barry McGrath, and Dr Philippe Guillem have received consulting fees, research or institutional support and educational grants from UCB. Dr Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB. Dr Philippe Guillem has received consultancy/advisory board disease-related honoraria from AbbVie, Novartis and UCB.
2. How does HS affect patients?
40:13||Season 1, Ep. 2This podcast is aimed at healthcare professionals, produced and funded by UCB. For our second episode, our host Dr Barry McGrath is joined by Professor Falk Bechara, the Head of the Department of Dermatologic Surgery at the Ruhr University Bochum, Germany. Together, they discuss the profound physical, psychological and social impacts that hidradenitis suppurativa can have on a patient’s quality of life. Please note, this episode briefly discusses suicide (20:28–22:35); listener discretion is advised. Speaker disclosures: Dr Barry McGrath and Professor Falk Bechara have received consulting fees, research or institutional support and educational grants from UCB. Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB. Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Incyte Corporation, Janssen-Cilag GmbH, MoonLake, Dr. Wolff, Mölnlycke and Celltrion. © UCB Biopharma SRL, 2024. All rights reserved. Date of preparation: January 2024 GL-DA-2400006
1. What is the bigger picture in HS?
32:43||Season 1, Ep. 1This podcast is aimed at healthcare professionals, produced and funded by UCB.This episode welcomes Dr John Ingram (HS Consultant Dermatologist at Cardiff University) to share an overview of what HS is, its presentation in patients, epidemiology and global prevalence. Speaker disclosures:Dr Barry McGrath and Dr John Ingram have received consulting fees, research or institutional support and educational grants from UCB.Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB.Dr John Ingram receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, and UCB, and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio. He is a co-copyright holder of HiSQOL, Investigator Global Assessment, and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. © UCB Biopharma SRL, 2023. All rights reserved.Date of preparation: December 2023IE-DA-2300159